Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com